Search

Your search keyword '"Khong, Hung"' showing total 189 results
Start Over Author "Khong, Hung"
189 results on '"Khong, Hung"'

3. Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Author

Soliman, Hatem, Hogue, Deanna, Han, Hyo, Mooney, Blaise, Costa, Ricardo, Lee, Marie C., Niell, Bethany, Williams, Angela, Chau, Alec, Falcon, Shannon, Soyano, Aixa, Armaghani, Avan, Khakpour, Nazanin, Weinfurtner, Robert J., Hoover, Susan, Kiluk, John, Laronga, Christine, Rosa, Marilin, Khong, Hung, and Czerniecki, Brian

Published
2023
Full Text
View/download PDF

5. CTIM-01. NIVOLUMAB AND STEREOTACTIC RADIOSURGERY (SRS) FOR PATIENTS WITH BREAST CANCER BRAIN METASTASES: LONG TERM RESULTS AND CELL FREE DNA (CFDNA) ASSESSMENT FROM A NON-RANDOMIZED, OPEN-LABEL, PHASE IB STUDY

Author

Ahmed, Kamran, primary, Kim, Youngchul, additional, Arrington, John, additional, Kim, Sungjune, additional, DeJesus, Michelle, additional, Soyano, Aixa, additional, Armaghani, Avan, additional, Costa, Ricardo, additional, Khong, Hung, additional, Loftus, Loretta, additional, Rosa, Marilin, additional, Caudell, Jimmy, additional, Diaz, Roberto, additional, Etame, Arnold, additional, Tran, Nam, additional, Soliman, Hatem, additional, Czerniecki, Brian, additional, Forsyth, Peter, additional, Yu, Hsiang-Hsuan Michael, additional, and Han, Hyo, additional

Published
2023
Full Text
View/download PDF

8. Abstract OT3-19-01: Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer

Author

Ahmed, Kamran A., primary, Kim, Youngchul, additional, Armaghani, Avan, additional, Arrington, John, additional, Costa, Ricardo, additional, Czerniecki, Brian J., additional, Diaz, Roberto, additional, Forsyth, Peter A., additional, Khong, Hung, additional, Lee, Kimberley, additional, Loftus, Loretta, additional, Rosa, Marilin, additional, Soliman, Hatem H., additional, Washington, Iman, additional, Soyano, Aixa, additional, and Han, Hyo S., additional

Published
2023
Full Text
View/download PDF

9. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Author

Bardia, Aditya, primary, Bidard, Francois-Clement, additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frederic, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, Jose Angel, additional, Bria, Emilio, additional, Cazzaniga, Marina Elena, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Tonini, Giulia, additional, Sahmoud, Tarek, additional, Habboubi, Nassir, additional, Grzegorzewski, Krzysztof, additional, and Kaklamani, Virginia, additional

Published
2023
Full Text
View/download PDF

10. 645 Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)

Author

Han, Hyo, primary, Evans, Elizabeth, additional, Fisher, Terrence, additional, Soliman, Hatem, additional, Khong, Hung, additional, Soyano, Aixa, additional, Costa, Ricardo, additional, Loftus, Loretta, additional, Lee, Kimberley, additional, Armaghani, Avan, additional, Liu, Hien, additional, Locke, Frederick, additional, Shrewsbury, Alexandria, additional, Malka, Jessica, additional, Karyampudi, Lavakumar, additional, Zauderer, Maurice, additional, and Czerniecki, Brian, additional

Published
2022
Full Text
View/download PDF

11. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, Francois-Clement, primary, Kaklamani, Virginia G., additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick M., additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García Sáenz, José A., additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Liu, Shubin, additional, Tonini, Giulia, additional, Laurent, Dirk, additional, Habboubi, Nassir, additional, Conlan, Maureen G., additional, and Bardia, Aditya, additional

Published
2022
Full Text
View/download PDF

13. Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

Author

Kaklamani, Virginia G., primary, Bardia, Aditya, additional, Aftimos, Philippe Georges, additional, Cortes, Javier, additional, Lu, Janice M., additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frederic, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joohyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen Kiernan, additional, Khong, Hung T., additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick Michael, additional, Tonini, Giulia, additional, Grzegorzewski, Kris, additional, and Bidard, François-Clement, additional

Published
2022
Full Text
View/download PDF

14. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, Bardia, Aditya, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, and Bardia, Aditya

Abstract

Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable mutations. Patients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; = .002) and patients with mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; = .0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively). Elacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

Published
2022

15. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, F, Kaklamani, V, Neven, P, Streich, G, Montero, A, Forget, F, Mouret-Reynier, M, Sohn, J, Taylor, D, Harnden, K, Khong, H, Kocsis, J, Dalenc, F, Dillon, P, Babu, S, Waters, S, Deleu, I, García Sáenz, J, Bria, E, Cazzaniga, M, Lu, J, Aftimos, P, Cortés, J, Liu, S, Tonini, G, Laurent, D, Habboubi, N, Conlan, M, Bardia, A, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, Bardia, Aditya, Bidard, F, Kaklamani, V, Neven, P, Streich, G, Montero, A, Forget, F, Mouret-Reynier, M, Sohn, J, Taylor, D, Harnden, K, Khong, H, Kocsis, J, Dalenc, F, Dillon, P, Babu, S, Waters, S, Deleu, I, García Sáenz, J, Bria, E, Cazzaniga, M, Lu, J, Aftimos, P, Cortés, J, Liu, S, Tonini, G, Laurent, D, Habboubi, N, Conlan, M, Bardia, A, Bidard, Francois-Clement, Kaklamani, Virginia G, Neven, Patrick, Streich, Guillermo, Montero, Alberto J, Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K, Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M, Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A, Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G, and Bardia, Aditya

Abstract

PURPOSE Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies.METHODSThis randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable ESR1 mutations.RESULTSPatients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). ESR1 mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P =.002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P =.0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively).CONCLUSIONElacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

Published
2022

16. A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes

Author

Bari,Shahla, Boulware,David, Li,Jiannong, Loftus,Loretta, Soyano Muller,Aixa, Jameel,Zena, Khong,Hung, Czerniecki,Brian J, Costa,Ricardo LB, Bari,Shahla, Boulware,David, Li,Jiannong, Loftus,Loretta, Soyano Muller,Aixa, Jameel,Zena, Khong,Hung, Czerniecki,Brian J, and Costa,Ricardo LB

Abstract

Shahla Bari,1 David Boulware,2 Jiannong Li,2 Loretta Loftus,3 Aixa Soyano Muller,3 Zena Jameel,4 Hung Khong,3 Brian J Czerniecki,3 Ricardo LB Costa3 1Department of Hematology/Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 3Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 4Department of Anatomic and Clinical Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Ricardo LB Costa, Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, Tel +813 745 3806, Fax +813 745 7287, Email ricardo.costa@moffitt.orgPurpose: Estrogen receptor-positive (ER+) breast cancer (BC) is a heterogeneous disease, and there is an ongoing debate regarding the optimal cut point for clinically relevant ER expression. We used a real-world database to assess the prognostic and predictive values of lower ER expression levels on treatment outcomes with endocrine therapy.Methods: We used a nationwide electronic health record database. Descriptive statistics were used to evaluate the association between ER expression, tumor characteristics, and treatment patterns among patients with early-stage BC. We used Kaplan–Meier survival curves to estimate recurrence-free survival (RFS) and overall survival (OS). We assessed associations between an alternative ER expression-level cut point and clinical outcomes.Results: Among 4697 patients with early-stage HER2-negative BC, 83 (2.04%) had ER+-low BC (ER expression, 1– 9.99%) and 36 (0.88%) had ER+-intermediate BC (10– 19.9%). ER+-low tumors were associated with higher tumor grade, larger size, and higher axillary tumor burden than ER+-high tumors (≥ 20% ER expression). African Americans had a higher prevalence of both triple-negative BC (TNBC) and ER+-low BC than ER+-high BC. Patients with ER

Published
2022

18. Abstract OT2-09-01: Phase I/II study of stereotactic radiation and abemaciclib in the management of hormone receptor positive HER2 negative breast cancer brain metastases

Author

Ahmed, Kamran A., primary, Kim, Youngchul, additional, DeJesus, Michelle, additional, Beyer, Sasha J., additional, Williams, Nicole O., additional, Palmer, Joshua, additional, Woodhouse, Kristina D., additional, Murthy, Rashmi K., additional, Li, Jing, additional, Armaghani, Avan J., additional, Arrington, John A., additional, Costa, Ricardo L., additional, Czerniecki, Brian J., additional, Etame, Arnold B., additional, Forsyth, Peter A., additional, Khong, Hung T., additional, Oliver, Daniel E., additional, Rosa, Marilin, additional, Sahebjam, Solmaz, additional, Soliman, Hatem H., additional, Soyano, Aixa E., additional, Vogelbaum, Michael A., additional, Yu, Michael, additional, and Han, Hyo S., additional

Published
2022
Full Text
View/download PDF

19. Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Author

Bardia, Aditya, primary, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Vuylsteke, Peter, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Kaklamani, Virginia, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, José, additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortes, Javier, additional, Liu, Shubin, additional, Laurent, Dirk, additional, Conlan, Maureen G., additional, and Bidard, Francois-Clement, additional

Published
2022
Full Text
View/download PDF

20. Abstract P2-14-01: Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer

Author

Han, Hyo S, primary, Costa, Ricardo, additional, Armaghani, Avan, additional, Soyano, Aixa, additional, Loftus, Loretta, additional, Soliman, Hatem, additional, Fridley, Brooke, additional, Whiting, Junmin, additional, Cerezo, Aiana, additional, Rosa, Marilin, additional, Extermann, Martine, additional, Khong, Hung, additional, and Czerniecki, Brian, additional

Published
2022
Full Text
View/download PDF

21. Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report

Author

Nativi-Nicolau, Jose, primary, Stehlik, Josef, additional, Kelkhoff, Aaron J., additional, Khong, Brian, additional, Truax, Crystal M., additional, Revelo, Monica P., additional, Gilbert, Edward Michael, additional, Drakos, Stavros, additional, Wever-Pinzon, Omar, additional, Fang, James, additional, Catino, Anna, additional, and Khong, Hung T., additional

Published
2022
Full Text
View/download PDF

22. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study

Author

Ahmed, Kamran A., primary, Kim, Youngchul, additional, Arrington, John A., additional, Kim, Sungjune, additional, DeJesus, Michelle, additional, Soyano, Aixa E., additional, Armaghani, Avan J., additional, Costa, Ricardo L.B., additional, Khong, Hung T., additional, Loftus, Loretta S., additional, Rosa, Marilin, additional, Caudell, Jimmy J., additional, Diaz, Roberto, additional, Robinson, Timothy J., additional, Etame, Arnold B., additional, Tran, Nam D., additional, Sahebjam, Solmaz, additional, Soliman, Hatem H., additional, Czerniecki, Brian J., additional, Forsyth, Peter A., additional, Yu, H. Michael, additional, and Han, Hyo S., additional

Published
2021
Full Text
View/download PDF

23. Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

Author

Sun, James, primary, Zhong, Xiaojun, additional, Ma, Junjie, additional, Sun, Weihong, additional, Han, Hyo S., additional, Soliman, Hatem H., additional, Loftus, Loretta S., additional, Costa, Ricardo L. B., additional, Armaghani, Avan J., additional, Soyano‐Muller, Aixa E., additional, Czerniecki, Brian J., additional, Lee, M. Catherine, additional, Kiluk, John V., additional, Khakpour, Nazanin, additional, Hoover, Susan J., additional, Laronga, Christine, additional, and Khong, Hung T., additional

Published
2021
Full Text
View/download PDF

28. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study.

Author

Ahmed, Kamran A., primary, Kim, Youngchul, additional, Arrington, John, additional, Kim, Sungjune, additional, DeJesus, Michelle, additional, Soyano, Aixa, additional, Armaghani, Avan J., additional, Costa, Ricardo L, additional, Khong, Hung T., additional, Rosa, Marilin, additional, Caudell, Jimmy J., additional, Diaz, Roberto, additional, Robinson, Timothy J., additional, Etame, Arnold B., additional, Tran, Nam D., additional, Sahebjam, Solmaz, additional, Soliman, Hatem Hussein, additional, Forsyth, Peter A. J., additional, Yu, Hsiang-Hsuan Michael, additional, and Han, Hyo S., additional

Published
2021
Full Text
View/download PDF

29. A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.

Author

Soliman, Hatem Hussein, primary, Han, Hyo S., additional, Hogue, Deanna, additional, Mooney, Blaise, additional, Costa, Ricardo L, additional, Lee, Marie Catherine, additional, Niell, Bethany, additional, Williams, Angela, additional, Chau, Alec, additional, Falcon, Shannon, additional, Khakpour, Nazanin, additional, Soyano, Aixa, additional, Armaghani, Avan J., additional, Weinfurtner, Robert J, additional, Hoover, Susan, additional, Kiluk, John, additional, Rosa, Marilin, additional, Fridley, Brooke, additional, Khong, Hung T., additional, and Czerniecki, Brian J., additional

Published
2021
Full Text
View/download PDF

31. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

Author

Soliman, Hatem, primary, Hogue, Deanna, additional, Han, Hyo, additional, Mooney, Blaise, additional, Costa, Ricardo, additional, Lee, Marie C., additional, Niell, Bethany, additional, Williams, Angela, additional, Chau, Alec, additional, Falcon, Shannon, additional, Khakpour, Nazanin, additional, Weinfurtner, Robert J., additional, Hoover, Susan, additional, Kiluk, John, additional, Rosa, Marilin, additional, Khong, Hung, additional, and Czerniecki, Brian, additional

Published
2021
Full Text
View/download PDF

32. Abstract OT-15-01: A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR+) breast cancer

Author

Khong, Hung T, primary, Goodridge, Dawn N, additional, Khakpour, Nazanin, additional, Lee, M. Catherine, additional, Laronga, Christine, additional, Armaghani, Avan J, additional, Soyano-Muller, Aixa E, additional, Han, Hyo, additional, Soliman, Hatem, additional, Costa, Ricardo, additional, Loftus, Loretta, additional, Hoover, Susan J, additional, Kiluk, John V, additional, Jameel, Zena, additional, and Czerniecki, Brian J, additional

Published
2021
Full Text
View/download PDF

33. Abstract PS3-09: The use of magnetic resonance imaging (MRI) in predicting pathological complete response(pCR) in the breast and axilla after the addition of immunotherapy to neoadjuvant systemic therapy (NST)

Author

Rajarajan, Noeline, primary, Segarra, Daniel, additional, Weinfurtner, Robert J, additional, Lopez, Adrian A, additional, Lee, M Catherine, additional, Kiluk, John, additional, Soliman, Hatem, additional, Khong, Hung, additional, Hyo, Han S, additional, Rosa, Marilin, additional, Czerniecki, Brian J, additional, and Khakpour, Nazanin, additional

Published
2021
Full Text
View/download PDF

36. 320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer

Author

Gandhi, Shipra, primary, Forsyth, Peter, additional, Opyrchal, Mateusz, additional, Ahmed, Kamran, additional, Khong, Hung, additional, Attwood, Kristopher, additional, Levine, Ellis, additional, O’Connor, Tracey, additional, Early, Amy, additional, Fenstermaker, Robert, additional, Prasad, Dheerendra, additional, Takabe, Kazuaki, additional, Czerniecki, Brian, additional, and Kalinski, Pawel, additional

Published
2020
Full Text
View/download PDF

37. Abstract CT185: A phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer

Author

Han, Hyo S., primary, Goodridge, Dawn, additional, Armaghani, Avan, additional, Costa, Ricardo, additional, Muller, Aixa Soyano, additional, Loftus, Loretta, additional, Soliman, Hatem, additional, Fridley, Brooke, additional, Khazai, Laila, additional, Cerezo, Aiana, additional, Hevia, Jesse, additional, Rosa, Marilin, additional, Khong, Hung, additional, and Czerniecki, Brian, additional

Published
2020
Full Text
View/download PDF

38. Abstract P2-17-03: Real-world benefit of CDK4/6 inhibitor and endocrine therapy combination in metastatic breast cancer and correlation with neutropenia

Author

Jenneman, Dakota, primary, Zhong, Xiaojun, additional, Ma, Junjie, additional, Sun, Weihong, additional, Han, Heather, additional, Soliman, Hatem, additional, Loftus, Loretta, additional, Costa, Ricardo, additional, Armaghani, Avan, additional, Soyano, Aixa, additional, Czerniecki, Brian, additional, Lee, M. Catherine, additional, Kiluk, John, additional, Khakpour, Nazanin, additional, Hoover, Susan, additional, Laronga, Christine, additional, and Khong, Hung T, additional

Published
2020
Full Text
View/download PDF

39. Abstract OT3-10-01: Phase Ib study of stereotactic radiation and nivolumab in the management of metastatic breast cancer with brain metastases

Author

Ahmed, Kamran A, primary, Kim, Youngchul, additional, Armaghani, Avan J., additional, Arrington, John A., additional, Caudell, Jimmy J., additional, Costa, Ricardo L., additional, Czerniecki, Brian J., additional, Etame, Arnold B., additional, Forsyth, Peter A., additional, Khong, Hung T., additional, Kim, Sungjune, additional, Loftus, Loretta, additional, Robinson, Timothy J., additional, Rosa, Marilin, additional, Sahebjam, Solmaz, additional, Soliman, Hatem H., additional, Soyano, Aixa E., additional, Tran, Nam D., additional, Yu, H. Michael, additional, and Han, Hyo S., additional

Published
2020
Full Text
View/download PDF

44. Abstract CT040: A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Author

Soliman, Hatem, primary, Hogue, Deanna, additional, Han, Hyo, additional, Mooney, Blaise, additional, Costa, Ricardo, additional, Lee, Marie C., additional, Niell, Bethany, additional, Khakapour, Nazanin, additional, Weinfurtner, Robert J., additional, Hoover, Susan, additional, Rosa, Marilin, additional, Khong, Hung, additional, and Czerniecki, Brian, additional

Published
2019
Full Text
View/download PDF

47. Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-γ and TNF-α

Author

Wang Yixiang, Radfar Soroosh, and Khong Hung T

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Approaches that enhance radiation effect may lead to improved clinical outcome and decrease toxicity. Here we investigated whether activated CD4+ T cells (aCD4) can serve as an effective radiosensitizer. Methods CD4+ T cells were activated with anti-CD3 and anti-CD28 mAbs. Hela cells were presensitized with aCD4 or conditioned supernatant (aCD4S) or recombinant cytokines for 2 days, followed γ-irradiation. The treated cells were cultured for an additional 2 to 5 days for cell proliferation, cell cycle, and western blot assays. For confirmation, other cancer cell lines were also used. Results Presensitization of tumor cells with aCD4 greatly increased tumor cell growth inhibition. Soluble factors secreted from activated CD4+ T cells were primarily responsible for the observed effect. IFN-γ seemed to play a major role. TNF-α, though inactive by itself, significantly augmented the radiosensitizing activity of IFN-γ. aCD4S, but not IFN-γ or IFN-γ/TNF-α combination, was found to enhance the γ-irradiation-induced G2/M phase arrest. Bax expression was highly upregulated in Hela cells presensitized with aCD4S followed by γ-irradiation. The radio-sensitizing activity of aCD4 is not uniquely observed with Hela cell line, but also seen with other cancer cell lines of various histology. Conclusions Our findings suggest possible molecular and cellular mechanisms that may help explain the radio-sensitization effect of activated lymphocytes, and may provide an improved strategy in the treatment of cancer with radiotherapy.

Published
2010
Full Text
View/download PDF

48. Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma

Author

Riker Adam I, Liu Suhu, Radfar Soroosh, Wang Yixiang, and Khong Hung T

Subjects
Medicine
Abstract

Abstract Background Melanoma incidence is on the rise and advanced melanoma carries an extremely poor prognosis. Treatment options, including chemotherapy and immunotherapy, are limited and offer low response rates and transient efficacy. Thus, identification of new melanocyte/melanoma antigens that serve as potential novel candidate biomarkers in melanoma is an important area for investigation. Methods Full length MITF-M and its splice variant cDNA were cloned from human melanoma cell line 624 mel by reverse transcription polymerase chain reaction (RT-PCR). Expression was investigated using regular and quantitative RT-PCR in three normal melanocytes (NHEM), 31 melanoma cell lines, 21 frozen melanoma tissue samples, 18 blood samples (pheripheral blood mononuclear cell; PBMC) from healthy donors and 12 non-melanoma cancer cell lines, including three breast, five glioma, one sarcoma, two kidney and one ovarian cancer cell lines. Results A novel splice variant of MITF-M, which we named MITF-Mdel, was identified. The predicted MITF-Mdel protein contains two in frame deletions, 56- and 6- amino acid deletions in exon 2 (from V32 to E87) and exon 6 (from A187 to T192), respectively. MITF-Mdel was widely expressed in melanocytes, melanoma cell lines and tissues, but almost undetectable in non-melanoma cell lines or PBMC from healthy donors. Both isoforms were expressed significantly higher in melanoma tissues than in cell lines. Two of 31 melanoma cell lines expressed only one isoform or the other. Conclusion MITF-Mdel, a novel melanocyte/melanoma-specific isoform of MITF-M, may serve as a potential candidate biomarker for diagnostic and follow-up purposes in melanoma.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results